Study of Cellutome System for Treatment of Individual Lesions in EB Pts

Status Completed

Clinical Trial Summary

Few but persistent wounds often remain even after successful hematopoietic cell transplantation for systemic genodermatosis epidermolysis bullosa (EB). The investigators propose local wound therapy using epidermal skin grafting from the same donor that provided the hematopoietic graft, or from the same EB individual with a mosaic (naturally gene corrected) skin. In both cases permissive immune system and skin chimerism is expected to enable long-term epidermal engraftment and wound healing. The investigators will use FDA approved vacuum device (CelluTome®, Regulation number 878.4820) that enables scar-free harvesting of epidermis and its transfer on a non-adherent silicone dressing (Adaptic) to the recipient as a wound dressing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Epidermolysis Bullosa

Clinical Trial Details

NCT number	NCT02670837
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact
Status	Completed
Phase	N/A
Start date	August 4, 2016
Completion date	April 3, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00380640` - The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa	Phase 2
Completed	`NCT00004761` - Establishment of the National Epidermolysis Bullosa Registry	N/A
Completed	`NCT01263379` - Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa	Phase 1/Phase 2
Completed	`NCT01716169` - Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care	N/A
Withdrawn	`NCT01454687` - Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes	N/A
Completed	`NCT00014729` - Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa	Phase 1
Recruiting	`NCT05838092` - Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)	Phase 3
Recruiting	`NCT03269474` - Computational Drug Repurposing for All EBS Cases
Completed	`NCT03068780` - Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa	Phase 3
Terminated	`NCT02090283` - Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa	Phase 2
Completed	`NCT02582775` - MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs	Phase 2
Recruiting	`NCT04213703` - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Completed	`NCT02384460` - ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa	Phase 3
Terminated	`NCT02670330` - Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa	Phase 3
Terminated	`NCT01619670` - A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa	Phase 4
Recruiting	`NCT01340235` - Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin	Phase 3
Completed	`NCT02014376` - Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa	Phase 2
Completed	`NCT04217538` - Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa
Completed	`NCT03942250` - Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients	N/A
Completed	`NCT01033552` - Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs	Phase 1/Phase 2